Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Enzyme-Linked Immunosorbent Assay01:33

Enzyme-Linked Immunosorbent Assay

In 1971, Peter Perlman and Eva Engvall developed an Enzyme-linked immunosorbent assay (ELISA or EIA). ELISA differs from western blot in that the assays are conducted in microtiter plates or in vivo rather than on an absorbent membrane.
There are many different types of ELISAs, but they all involve an antibody molecule whose constant region binds an enzyme, leaving the variable region free to bind its specific antigen.  Enzyme-substrate reaction allows the antigen to be visualized or quantified.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Visual disability accommodations and ophthalmology.

BMJ open ophthalmology·2026
Same author

Vision loss, disability and multimorbidity among older people in Andhra Pradesh and Telangana in South India: the longitudinal eye health, ageing and disability study (LEADS) - study protocol.

BMJ public health·2026
Same author

A Clinically Relevant Threshold of Impaired Contrast Sensitivity Among Older US Adults.

JAMA ophthalmology·2026
Same author

Locally-affiliated authorship in global eye health research conducted in Sub-Saharan Africa between 2003 and 2022.

Eye (London, England)·2026
Same author

Visual Impairment and Driving in Older Adults: A Narrative Review.

Current treatment options in neurology·2026
Same author

Well-child vision screening outcomes and guideline adherence at two major academic health systems in the United States.

Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus·2026

Related Experiment Video

Updated: Jun 6, 2026

Generation of Two-color Antigen Microarrays for the Simultaneous Detection of IgG and IgM Autoantibodies
10:16

Generation of Two-color Antigen Microarrays for the Simultaneous Detection of IgG and IgM Autoantibodies

Published on: September 15, 2016

A native antigen "reverse capture" microarray platform for autoantibody profiling of prostate cancer sera.

Joshua R Ehrlich1, Robert J Caiazzo, Weiliang Qiu

  • 1Molecular Urology Laboratory, Division of Urology, and the Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Proteomics. Clinical Applications
|December 8, 2010
PubMed
Summary

This study introduces a novel microarray to detect autoantibodies in prostate cancer patients. This method identifies specific autoantigens that can help differentiate prostate cancer from benign prostate hyperplasia (BPH).

More Related Videos

Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
15:17

Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing

Published on: September 25, 2011

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Related Experiment Videos

Last Updated: Jun 6, 2026

Generation of Two-color Antigen Microarrays for the Simultaneous Detection of IgG and IgM Autoantibodies
10:16

Generation of Two-color Antigen Microarrays for the Simultaneous Detection of IgG and IgM Autoantibodies

Published on: September 15, 2016

Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
15:17

Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing

Published on: September 25, 2011

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • Cancerous sera contain autoantibodies targeting autologous cellular antigens.
  • Distinguishing prostate cancer from benign prostate hyperplasia (BPH) is clinically significant.
  • Current diagnostic methods may require further refinement for accurate differentiation.

Purpose of the Study:

  • To develop and validate a novel native antigen-based platform for identifying autoantigens.
  • To assess the potential of autoantibody expression profiles in differentiating prostate cancer from BPH.
  • To identify specific autoantigens that can serve as biomarkers for prostate cancer detection.

Main Methods:

  • Utilized a "reverse capture" autoantibody microarray platform.
  • Purified and differentially labeled IgG from prostate cancer and BPH patient sera.
  • Performed competitive hybridization experiments with dye-swapping for robust data acquisition.

Main Results:

  • Identified 28 unique antigen-autoantibody reactivities with potential to discriminate prostate cancer from BPH (p-value ≤0.01).
  • Identified autoantigens fall into categories including protein kinases, cell-cycle regulators, and apoptosis mediators.
  • Only one autoantigen remained differentially targeted post-surgery, suggesting specificity for active disease.

Conclusions:

  • Autoantibody profiling using the reverse capture microarray platform shows promise for differentiating malignant from benign prostate diseases.
  • The identified autoantigens represent potential novel biomarkers for prostate cancer diagnosis.
  • This platform offers a sensitive approach for biomarker discovery in complex diseases.